Conference abstractPublished 2018

Clinical immunogenic chemotherapy in refractory sarcoma

Authors: Pedro Alejandro Lucero Diaz

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: There are several studies of the effects of the classic cancer cytotoxic chemotherapy used low doses but in animal models. With that in mind, we performed a systematic review to select at least four potential drugs and prepare dose-response and time-effect curves using cell lines from soft tissue sarcoma. We found the doxorubicin and oxaliplatin were cell lines. Also, we evaluated the able to kill a low dose tumor cells even chemoresistant potential activation of the adaptive immune cells and dendritic cells in fresh PMBC to make the ratio of killing tumor cells and activate simultaneously the CD8 and Th1 cells. Both drugs at low doses meaning immunogenic chemotherapy were able to kill tumor cells but also activate several cells of the immune system. Methods: 10 patients with soft tissue sarcoma were treated with 20 mg total of doxorubicin and 30 mg total dose of oxaliplatin. These doses were selected in base in our in vitro studies. After the local IRB ethics committee, we treated the patients twice having as end point the granzyme production measured by granzyme B and by cytotoxicity assays measured the tumor cells death. We cultured the dendritic cells and we measured IL-12 as surrogate marker. Results: 8/10 patients improved statistically significant the granzyme production against four recall antigens and 10 tumorassociated antigens after the month of treatment. The treatment was well tolerated, and we continued the treatment until tumor progression. With one month of treatment 60% of the patients undergo tumor reduction demonstrated by CT scan. Responder patients had high-production of granzyme against a cocktail of four tumor-associated antigens (p=0.005). Discussion: Clinical immunogenic chemotherapy with doxorubicin and oxaliplatin was able to improve CD8 cells and some patients even in a month of treatment had tumor reductions. We decided to keep with the treatment until disease progression and we will add multi peptide immunotherapy and immunomodulation in a separate pilot protocol to see if we can improve clinical outcomes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Archives in Cancer Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalArchives in Cancer Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Pedro Alejandro Lucero Diaz”